A Chinese Retrospective Multicenter Study of First-Line Chemotherapy for Advanced Pancreatic Cancer

Hanzhi Cui; Jingzhi Guan; Guochao Deng; Jiajia Yuan; Changjie Lou; Wen Zhang; Aiping Zhou; Yanqiao Zhang; Jun Zhou; Guanghai Dai

doi:10.12659/MSM.927654

26 October 2020 : Clinical Research

A Chinese Retrospective Multicenter Study of First-Line Chemotherapy for Advanced Pancreatic Cancer

Hanzhi Cui^12BCDEF*, Jingzhi Guan^2D, Guochao Deng^2B, Jiajia Yuan^3B, Changjie Lou^4B, Wen Zhang^5B, Aiping Zhou^5BD, Yanqiao Zhang^4D, Jun Zhou^3D, Guanghai Dai^6ADG

DOI: 10.12659/MSM.927654

Med Sci Monit 2020; 26:e927654

Authors information Article notes Copyright and License information

Related articles Order reprints Share article Share by email

View HTML version

Figure 2 Kaplan-Meier curve of overall survival (OS) and progression-free survival (PFS) in patients treated with the regimens. (A) OS in patients treated with nab-paclitaxel and S-1 (AS), ab-paclitaxel and gemcitabine (AG), and 5-fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX). (B) PFS of patients treated with the AS, AG, and FOLFIRINOX.

Back to the Article

A Chinese Retrospective Multicenter Study of First-Line Chemotherapy for Advanced Pancreatic Cancer

Your Privacy